x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Power to the Patients

Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today"s systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com

science life sciences

All Episodes

31:48

Beyond Dopamine: Why Traditional Schizophrenia...

Power to the Patients ·

2026/02/04

In this episode of Power to the Patients, Brandon Li sits down with Dr. Laxminarayan Bhat, Founder and CEO of Reviva Pharmaceuticals, to explore groundbreaking developments in schizophrenia treatment. Dr. Bhat shares insights on his company's innovative drug that shows promising results with fewer side effects and better patient adherence than existing treatments. Discover how their unique approach to targeting serotonin-dopamine signaling, combined with reduced off-target effects, could transform

en

53:14

The 20-Year Industry Secret: Redefining...

Power to the Patients ·

2026/01/09

In this episode of Power to the Patients, Brandon Li sits down with Dr. Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, to explore how targeting the adrenergic system could offer both symptomatic relief and disease-modifying potential for Alzheimer's, Parkinson's, and depression. From his two decades developing breakthrough therapies in neurology and psychiatry, including the migraine treatment Erenumab, Dr. Vargas breaks down translational medicine, challenges the amyloid hypothesis,

en

35:28

3 Diseases, 1 Mechanism: The Breakthrough Changing...

Power to the Patients ·

2025/12/03

What if inflammation was the key to unlocking treatments for Alzheimer's, Parkinson's, and Long COVID? In this episode of Power to the Patients, Brandon Li sits down with Cuong Do, CEO of BioVie, to explore the fascinating intersection of these seemingly unrelated conditions. From diving into medical research at the age of 14 to leading groundbreaking clinical trials, Cuong shares invaluable insights on biotech innovation, trial design, and navigating today's challenging funding landscape. Tune in

en

42:21

Why Traditional Psychedelics Miss 90% of Neurology...

Power to the Patients ·

2025/11/12

In this episode of Power to the Patients, Brandon Li sits down with Dr. Chris Witowski, CEO and Co-Founder of Psilera, to explore the fascinating intersection of psychedelics and neurodegeneration. Discover how non-hallucinogenic compounds could revolutionize treatments for conditions like frontotemporal dementia, why traditional psychedelics may have overlooked neurodegenerative applications, and the future of neuroplasticity-based therapies. From biomarker development to innovative drug delivery

en

39:56

Inside the ALS Breakthrough: 20-Year Journey to FDA...

Power to the Patients ·

2025/11/05

In this episode of Power to the Patients, Brandon Li and Dr. Palumbo, Chief Medical Officer at BioVie Pharma, explore the evolving landscape of neuroscience research, the critical differences between big pharma and biotech approaches, and promising new pathways for treating conditions like Parkinson's and Alzheimer's. Whether you're a researcher, clinician, or industry professional, this conversation offers a fascinating look at how inflammation-focused treatments and systems biology could

en

40:54

Why Clinical Trial Speed Kills Success - And What Top...

Power to the Patients ·

2025/10/21

What if you could learn the secrets behind one of psychiatry's most significant breakthroughs in decades? In this episode of Power to the Patients, host Brandon Li sits down with Steve Brannan, Chief Medical Officer of Karuna Therapeutics, to explore the art of clinical trial excellence, the future of precision psychiatry, and the untold story behind developing the first new-mechanism schizophrenia drug in decades. Whether you're a researcher, clinician, or industry professional, this conversation

en

50:05

Dr. Anantha Shekhar on the Convergence of Psychiatry,...

Power to the Patients ·

2025/10/15

In this episode of Power to the Patients, Brandon Li speaks with Dr. Anantha Shekhar, Senior Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of Pittsburgh. Dr. Shekhar shares how his early experiences with a family member’s schizophrenia inspired a lifelong mission to bridge neuroscience, psychiatry, and translational research. They explore how psychiatry and neurology are rapidly converging, why the future of mental health treatment lies in understanding

en

39:42

Ram Mukunda, CEO of IGC Pharma, on Innovation and...

Power to the Patients ·

2025/09/23

In this episode of Power to the Patients, Brandon Li speaks with Ram Mukunda, CEO of IGC, about groundbreaking approaches to Alzheimer’s care. Ram shares how his team is developing an ultra-low dose THC-based therapy to reduce agitation and neuroinflammation without sedation, and how AI models may transform early diagnosis for millions worldwide. Their conversation highlights both the science and the human urgency behind innovating for patients and caregivers facing Alzheimer’s.

en

68:18

Brandon Bentzley, CSO and Co-founder of Magnus...

Power to the Patients ·

2025/09/17

What if we could treat severe depression in just five days — and give patients back the cognitive control to live their true lives? This week on Power to the Patients, we sit down with Brandon Bentzley, MD, PhD, co-founder and Chief Scientific Officer at Magnus Medical, to talk about the future of precision psychiatry and the breakthrough SAINT™ protocol.

en

50:28

Sarah MacCallum & Melissa Gaines- Clinical Operations...

Power to the Patients ·

2025/09/10

What does great clinical operations really look like? In this episode, Sarah MacCallum and Melissa Gaines of Annovis Bio share their journeys into clinops and the lessons they’ve learned leading Alzheimer’s and neurology trials. From choosing the right site partners to keeping engagement high, to navigating the unique challenges of working with vulnerable populations, they break down what it takes to run trials that truly make an impact.

en

45:45

Daniel O'Connell, CEO of Acumen Pharmaceuticals, on...

Power to the Patients ·

2025/09/05

With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on Acumen — from its origins as a seed-stage idea to today’s phase 2 clinical trial, Altitude AD. He explains the science behind targeting amyloid beta oligomers (rather than plaques), what makes Alzheimer’s research uniquely difficult, and why recent advances in biomarkers, trial design, and patient recruitment give him hope for meaningful progress.

en

55:40

Michael Gold, Chief R&D Officer at Compass Pathways

Power to the Patients ·

2025/08/26

In this episode, Brandon sits down with Dr. Michael Gold, Chief R&D Officer at Compass Pathways, to explore the art and science of running high-quality clinical trials. With nearly 30 years of experience across pharma giants like J&J and GSK, as well as small biotechs, Mike shares a masterclass on clinical operations—why the best study design means nothing without flawless execution, and how quality must always come before speed or cost.

en

56:17

Matthew Leoni, CMO of Merida Biosciences, on...

Power to the Patients ·

2025/08/14

Brandon Li talks with Matt Leoni—former Senior VP of Global Clinical Development at Cerevel and now Chief Medical Officer at Merida Biosciences. Matt shares his journey from medical school to leading late-stage drug development in neuroscience. He discusses the unique challenges of neuro drug development, from the subjectivity of endpoints and high placebo response rates to the operational hurdles of large-scale trials. Matt offers candid insights into why promising drugs sometimes fail, the

en

00:56:17

Matthew Leoni, CMO of Merida Biosciences, on...

Power to the Patients ·

2025/08/14

Brandon Li talks with Matt Leoni—former Senior VP of Global Clinical Development at Cerevel and now Chief Medical Officer at Merida Biosciences. Matt shares his journey from medical school to leading late-stage drug development in neuroscience. He discusses the unique challenges of neuro drug development, from the subjectivity of endpoints and high placebo response rates to the operational hurdles of large-scale trials. Matt offers candid insights into

en

53:47

Gerard Sanacora, Professor at Yale, on glutamate,...

Power to the Patients ·

2025/06/19

Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate, and rapid-acting antidepressants. Gerard shares how a surprising finding in patients undergoing ECT redirected his research toward depression—and eventually to ketamine. Their conversation explores the science of neuroplasticity, the complexities behind ketamine’s mechanism of action, and how interventional psychiatry and digital tools may

en

00:53:47

Gerard Sanacora, Professor at Yale, on glutamate,...

Power to the Patients ·

2025/06/19

Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate, and rapid-acting antidepressants. Gerard shares how a surprising finding in patients undergoing ECT redirected his research toward depression—and eventually to ketamine. Their conversation explores the science of neuroplasticity, the complexities behind ketamine’s mechanism of action, and how

en

00:53:47

Gerard Sanacora, Professor at Yale, on glutamate,...

Power to the Patients ·

2025/06/19

Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate, and rapid-acting antidepressants. Gerard shares how a surprising finding in patients undergoing ECT redirected his research toward depression—and eventually to ketamine. Their conversation explores the science of neuroplasticity, the complexities behind ketamine’s mechanism of action, and how

en

39:35

Backing Breakthroughs in Psychedelics

Power to the Patients ·

2025/06/06

Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful

en

00:39:35

Backing Breakthroughs in Psychedelics

Power to the Patients ·

2025/06/06

Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A

en

00:39:35

Backing Breakthroughs in Psychedelics

Power to the Patients ·

2025/06/06

Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A

en

107 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter